Improved techniques to noninvasively image protein-protein interactions (PPIs) are essential. We molecularly engineered a positron emission tomography (PET)-based split reporter (herpes simplex virus type 1 thymidine kinase), cleaved between Thr265 and Ala266, and used this in a proteinfragment complementation assay (PCA) to quantify PPIs in mammalian cells and to microPET image them in living mice. An introduced point mutation (V119C) markedly enhanced thymidine kinase complementation in PCAs, on the basis of rapamycin modulation of FKBP12-rapamycin-binding domain (FRB) and FKBP12 (FK506 binding protein), the interaction of hypoxia-inducible factor-1 with the von Hippel-Lindau tumor suppressor, and in an estrogen receptor intramolecular protein folding assay. Applications of this unique split thymidine kinase are potentially far reaching, including, for example, considerably more accurate monitoring of immune and stem cell therapies, allowing for fully quantitative and tomographic PET localization of PPIs in preclinical small-and large-animal models of disease.
Improved techniques to noninvasively image protein-protein interactions (PPIs) are essential. We molecularly engineered a positron emission tomography (PET)-based split reporter (herpes simplex virus type 1 thymidine kinase), cleaved between Thr265 and Ala266, and used this in a proteinfragment complementation assay (PCA) to quantify PPIs in mammalian cells and to microPET image them in living mice. An introduced point mutation (V119C) markedly enhanced thymidine kinase complementation in PCAs, on the basis of rapamycin modulation of FKBP12-rapamycin-binding domain (FRB) and FKBP12 (FK506 binding protein), the interaction of hypoxia-inducible factor-1 with the von Hippel-Lindau tumor suppressor, and in an estrogen receptor intramolecular protein folding assay. Applications of this unique split thymidine kinase are potentially far reaching, including, for example, considerably more accurate monitoring of immune and stem cell therapies, allowing for fully quantitative and tomographic PET localization of PPIs in preclinical small-and large-animal models of disease.
PPIs are vital to most cellular functions, being associated with proc esses as diverse as enzymatic activity, signal transduction, immuno logical recognition and DNA repair and replication 1 . A multitude of experimental qualitative and quantitative techniques have been developed with the common goal of understanding these ubiquitous interactions 2 . Herein we describe the construction and validation of a new split reporter for use in a PCA strategy to quantitatively image and define PPIs in living subjects by PET. We have previously reviewed the many noteworthy advantages of molecular imaging of biological processes in living subjects 3 . The noninvasive visual representation, characterization, quantification and timing of PPIs could create new opportunities to complement available in vitro or cell culture methodo logies to accelerate the evaluation in living subjects of new drugs that promote or inhibit active homodimeric or heterodimeric protein assembly and to characterize more fully known PPIs (for example, the reasons for, and the factors that drive, their association) in the context of wholebody, physiologically authentic environments.
In all PCAs, splitting a specific reporter protein into two distinct fragments abolishes its function. Bringing the two fragments back together in a controlled manner, as might occur when driven by a par ticular PPI under scrutiny, then restores partial functional activity of the reporter and thus reflects on the occurrence and nature of the PPI 4 ( Fig. 1a) . Selected fragments of many proteins can associate to produce functional bimolecular complexes 5 . Split reporter systems have been used to date in several model organisms, including Escherichia coli 6 , yeast 7 , Caenorhabditis elegans 8 and mice 9, 10 .
The herpes simplex virus type 1 thymidine kinase (HSV1TK, encoded by tk) enzyme phosphorylates a wide range of nucleoside analogs, allowing selective antiherpetic and viral vector-based gene therapies. The two main categories of substrates for thymidine kinase, uracil nucleoside derivatives labeled with radioactive iodine (for example, 2′fluoro2′deoxy1betadarabinofuranosyl5iodo uracil) 11 or radiolabeled 2′fluoro2′deoxyarabinofuranosyl5ethyl uracil 12 , and acycloguanosine derivatives labeled with radioactive 18 Ffluorine (for example, fluoropenciclovir [or 9(4[ 18 F]fluoro3 hydroxymethylbutyl)guanine (FHBG)) 13 , have been investigated in the last few years as reporter probes for imaging HSV1tk reporter gene expression 14 . These radiolabeled reporter probes are transported into cells and are trapped as a result of phosphorylation by thymi dine kinase. When used in nonpharmacological tracer doses, these substrates can serve as PET or singlephoton emission computed tomography (SPECT)targeted reporter probes, as they accumulate only in the cells expressing the HSV1tk gene.
Herein we describe the molecular engineering rationale and con struction of a new split thymidine kinase reporter, cleaved into two fragments between Thr265 and Ala266, for use in a PCA to quanti tatively measure realtime PPIs in mammalian cells using cell uptake studies and to PET image the PPIs in subcutaneous implants in living mice. We also introduced a point mutation (V119C) in the Nterminal fragment of the split thymidine kinase reporter to enhance the degree of PPIinduced reporter complementation. Of note, the thymidine kinase PCA approach that we describe has the potential to provide a sensitive and more accurate means of in vivo fully quantitative imaging and precise tomographic localization of PPIs deeper in the body than currently possible with any other imaging technique. Optical bioluminescence imaging, by contrast, and rather restrictingly, is relatively surface weighted and semiquantitative in nature. Our method will probably result in a marked benefit when attempting accurate study of more representative animal models (as compared to xenograft models) of disease based on orthotopic cellular implants, particularly in transgenic animal applications during the preclinical drug discovery and validation processes 15 . Future applications in humans may also be possible in theory, for example, when using split reporters to PET image relevant PPIs in cell therapeutic strategies after ex vivo transduction of cells of interest.
RESULTS

Design of the thymidine kinase PCA strategy
We first performed a partial circular permutation screen of the thymi dine kinase molecule and deemed it likely that a split between Thr265 and Ala266 would produce two protein fragments that could be further tested in a PCA strategy for imaging PPIs (Supplementary Methods, Supplementary Table 1 , Supplementary Fig. 1 and Supplementary Discussion). We next determined whether removal of the linker join ing the native N and Cterminal ends in circular permuted thymidine kinase split at residues 265 and 266 would yield a pair of thymidine kinase fragments that could function and complement in a PCA strat egy 16 . We used the two heterologous human proteins FRB and FKBP12, which are known to strongly interact in the presence of rapamycin 17 . The use of the FRBFKBP12rapamycin system is an example of an intermolecular 'threehybrid' interaction in which a third partner (for example, a small ligand, rapamycin in this case) mediates a PPI 18 . The value of this test system has been shown in several previous PCA strategies, including the dihydrofolate reductase fragment comple mentation assay 18 and those using split firefly luciferase 9 and Renilla luciferase 10 . The Nterminal thymidine kinase fragment comprising amino acids 1-265 (nTK) was fused (via an intervening flexible tenresidue linker [GGGGS] 2 ) proximal to the Nterminal end of FRB to yield the chimeric protein nTKFRB. The Cterminal thymidine kinase fragment comprising amino acids 266-376 (cTK) was fused (via a similar linker) distal to the Cterminal end of FKBP12 to yield the chimeric protein FKBP12cTK (Fig. 1b) . We initially used this particular orientation because it was successful in previously published PCA strategies, for example, when using split firefly luciferase 9 , and Renilla luciferase 10 ; the same FRBFKBP12 heterodimerization system was used in both cases. We tested the interaction between these proteins (FRB and FKBP12, modulated by rapamycin) after transient coexpression of the fusion proteins in 293T cells where there is no endogenous HSV1tk expression, followed by an in vitro thymidine kinase enzyme cellular uptake assay to detect dimerizationassisted complementation of the thymidine kinase fragments.
We introduced a point mutation (V119C) into thymidine kinase to obtain a variant that permits disulfide bond formation and crosslinking of two thymidine kinase monomers covalently 19 . We found that the use of nTK fragments carrying this point mutation resulted in 41% increased enhancement (which was at the limit of statistical significance) Figure 1 Principle of the thymidine kinase PCA, expression vectors used and evaluation of plasmid vector constructs containing the V119C mutation. (a) Schematic diagram showing the PCA strategy using split HSV1-TK (here abbreviated as TK) to monitor the hypothetical X-Y heterodimeric protein-protein interaction. This is a simplified schematic diagram representing the forward or 'folding' mechanism underlying a PCA. The reverse or 'unfolding' mechanism is not depicted here for the sake of simplification. A more realistic and detailed graphic depiction of the interplay between these two mechanisms within a PCA has been published previously 26 
of the degree of PPIinduced complementation of thymidine kinase fragments, as compared with use of nonmutated nTK, when studied 36 h after transient transfection in 293T cells ( Fig. 1c) . All experimental results related to further optimization of the thymidine kinase PCA, before and after constructing this V119C variant, as well as further extensive experiments designed to validate the functional activity of the constructs used, are presented in the Supplementary Methods, Supplementary Discussion and Supplementary Figures 2-19 . Of note, we also established that attaching interacting proteins (FRB or FKBP12) to separate nTK and cTK fragments did not perceptibly hinder the subcellular trafficking of the split reporter when com pared to the localization of the normal fulllength thymidine kinase molecule ( Fig. 2a,b) .
Testing the new PCA in separate cell lines and PPI systems Because 293T cells are designed for multiepisomal replication and high levels of protein expression, we tested the combination of opti mally oriented chimeras in two other cell lines (SKBr3 human breast cancer and SKOV3 human ovarian cancer) not specifically used for that purpose. True to the features of the developed thymidine kinase PCA, these also yielded an approximate threefold rise in split thymi dine kinase complementation upon PPI (Fig. 3a) .
To further demonstrate the general applicability of the engineered split thymidine kinase fragments, we also tested their complementa tion in two other separate systems. First, we used a system that also employs an intermolecular PPI of hypoxiainducible factor (its sub unit 1α, HIF1α) and the von HippelLindau tumor suppressor (VHL) (Supplementary Discussion) 20 . HIF1α is a transcriptional complex that is central in the regulation of gene expression by oxygen, and VHL serves as the recognition component of a ubiquitin ligase that promotes ubiquitindependent proteolysis of HIF1α. In hypoxic cells (desferrioxamine is an iron chelator with 'hypoxiamimetic' activity; desferrioxamine stabilizes HIF1α from proteolysis by inhibiting the activity of irondependent prolyl hydroxy lases), HIF1α degradation is suppressed owing to a diminished interaction with VHL. To test this system, we constructed a vector that transiently expresses a fusion protein with split thymidine kinase fragments (con taining the V119C point mutation) and sub stituting FRB with HIF1α and FKBP12 with VHL. We studied this system in 293T cells after treatment with various doses of desferri oxamine. There was a substantial level of split thymidine kinase complementation (62.2% of activity of intact thymidine kinase) upon interaction between HIF1α and VHL, which diminished with exposure to increasing concentra tions of desferrioxamine (Fig. 3b ).
The second system used an intramolecular proteinfolding sensor; we designed and validated this system previously by encoding various human estrogen receptor ligandbinding domain fusion proteins that could lead to split reporter complementation in the presence of the appropriate ligands 21 . There was a significant level (P < 0.05) of ligandinduced split thymidine kinase complementation for several ligands, except for genistein, in a similar pattern to that documented previously for complementation of split synthetic Renilla luciferase complementation 21 (Fig. 3c) . We conducted all experiments in com parison to a positive control derived from the activity of intact thymi dine kinase and a mock transfection acting as a negative control.
MicroPET imaging of PPIs in subcutaneous xenografts in mice Next, we imaged five mice subcutaneously injected with 293T cells stably expressing nTK V119C FRB plus FKBP12cTK from a single vector with the [ 18 F]FHBG probe and microPET in the presence of rapamycin. We quantified the signal from each implant directly from the microPET images to determine the percentage injected dose per g for the FHBG probe. We initially allowed these five mice to grow 1weekold subcutaneous xenografts of 293T cells stably expressing nTK V119C FRB plus FKBP12cTK on one shoulder and control tumors (mocktransfected 293T cells) on the other shoulder before microPET imaging before and 24 h after exposure to 50 μg of rapamycin. The mice were repeatedly imaged on day 1 (before rapamycin), day 2 (one dose after rapamycin) and day 5 (three doses after rapamycin) of this imaging protocol, that is after 1 week of intial xenograft growth. The incremental increases in mean percentage injected dose per g values for FHBG accumulation in the tumor formed by cells stably expressing nTK (V119C) FRB plus FKBP12cTK were well demonstrated (Fig. 4a) . We made comparisons with the control tumor showing background signal. We observed statistically significant differences in imaging signal in tumors expressing split thymidine kinase plus the inter acting proteins when comparing probe accumulation before and after injection of rapamycin (P = 0.02 on imaging day 5) ( Fig. 4b) .
Only background signal was obtained from both implanted xenografts in a separate cohort of four control mice not receiving rapamycin (data not shown). In another group of four mice, xenografts express ing nTK V119C FRB plus FKBP12cTK were compared with control implants stably expressing nTK plus cTK only (also in a single vector).
There was minimal FHBG accumulation in the control tumors on the fifth day of a similar imaging protocol to that described above for use of a single vector incorporating nTK V119C FRB plus FKBP12cTK (Fig. 4c) . We also carried out preliminary pilot imaging studies of transiently transfected cells in three mice using C6 cells stably trans fected with HSV1sr39tk as positive controls (data not shown).
As anticipated, the microPET detected counts from shoulder tumors expressing split thymidine kinase plus interacting proteins did not differ in significance whether the mice were imaged in the supine or prone positions (probe percentage injected dose per gram of 0.89 and 1.02, respectively, Fig. 5 ). Optical cooled chargecoupled device (CCD) camera bioluminescence imaging of the concurrently injected 293T cells stably expressing firefly luciferase (see Supplementary Methods) showed equivalent signal from both control and experimen tal tumors in all of the mice used for microPET imaging, reflecting on the equivalent cell load and viability in all tumors under study (Fig. 4a) . However, these optical imaging findings were evident only upon imaging the mice in the prone position, with a peak light emission of 2.3 × 10 5 p s −1 cm −2 sr −1 (Fig. 5) . In contrast, when the mice were imaged in the supine position, the light emanating from subcutaneous xenografts on the shoulder and back did not penetrate through the full thickness of the mouse (the mouse torso being >1 cm thick) ( Fig. 5) . These findings highlight the relative advantage of PET over optical imaging in imaging sources of signal at depths greater than 1 cm from the exterior, which is a wellknown advantage of PET over optical bioluminescence imaging.
DISCUSSION
Typical PPIs represent lowlevel biological events and are thus chal lenging to locate and image in intact living subjects. PET, in part owing to its sensitivity and its fully quantitative and tomographic nature, is one of the few noninvasive imaging technologies that currently can be applied in humans for in vivo monitoring of reporter gene expression and that has the potential to image complex biological phenomena such as PPIs 22 . To create a PETbased PCA using thymidine kinase, the first step was to identify sites where we could disrupt the primary amino acid sequence of thymidine kinase to separate the enzyme into two complementary protein fragments. The circularly permuted variant (where the split site was between Thr265 and Ala266) was the only mutation to retain thymidine kinase enzymatic activity (85.2%, as compared to full length normal HSV1sr39TK). We next exhaustively studied these engineered thymidine kinase fragments with respect to their orientation in interacting chimeras, temporal changes in com plementation and the dosage of a modulating drug (rapamycin) for heterodimerizationinduced complementation. We also scrutinized the characteristics of these newly engineered fragments in a variety of cell lines and interacting protein systems. Further detailed analysis and validation was undertaken with regard to issues of self comple mentation and steric hindrance, testing of a pointmutated version of split thymidine kinase, the reversibility of the thymidine kinase PCA and microPET imaging in living mice. A more detailed analysis is presented in the Supplementary Discussion.
In essence, the molecular engineering efforts employed in this study, like all protein engineering, are concerned with adapting proteins to function under different regimes 23 . In this regard, most protein engi neering used so far in general, and in attempts to split thymidine kinase more specifically, have been by 'rational redesign' 23 , that is precon ceived alterations based on a detailed knowledge of protein structure, function and mechanism 24 . The alternative approach in enzyme engi neering is through 'directed evolution' , whereby libraries of mutated genes (normally created by using errorprone PCR 24 , but in this case these 'mutations' would be split genes that express fragments of thymidine kinase) are created, and genetic selection or highthrough put screening is subsequently used to identify the mutants (that is, the split fragments) that possess retained thymidine kinase activity. Although either rational redesign or directed evolution can be very effective, a combination of both strategies would probably represent the most successful route in future studies aimed at further refinement of the above strategies to obtain betterfunctioning split thymidine kinase fragments (showing greater proteinprotein interactioninduced complementation with less self complementation) for use in a splitreporter PCA strategy for PET imaging of PPIs 24 .
In conclusion, the development and comprehensive proofofprinciple validation of our engineered thymidine kinase PCA now pave the way for more research directions to enable improved tomographic localization and quantitative imaging of PPIs, signal transduction cascades and systemsbiology networks in transgenic animal models Figure 5 The relative advantage of PET over optical imaging in imaging sources of signal at depths below 1 cm from the exterior is exemplified in this experiment. Five mice were imaged 6 d after implantation with 5 × 10 6 293T cells stably expressing thymidine kinase or firefly luciferase (FLUC). The microPET signal return (FHBG accumulation in percentage ID per g) from shoulder tumors (circled) expressing thymidine kinase did not differ in significance whether the mice were imaged in the supine or prone positions (probe percentage ID per g of 0.89 and 1.02, respectively), as demonstrated in the transaxial and coronal tomographic images of representative mice (intense accumulation in center and lower aspect of coronal images is due to nonspecific probe excretion in the gut). When imaged in the supine position, the light emanating from subcutaneous xenografts on the shoulder or back showed no penetration through the full thickness of the mouse.
of disease 25 . The application of this particular innovation to PET imaging also heralds other potential research directions that could lead to a successful split reporter-based strategy for future clinical imaging of PPIs in humans.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METHODS
Preparation and testing of 293T stable cells. To make stable cells, we incu bated 5 × 10 6 293T cells plated in a 10cm dish for 24 h at 37 °C with 95% oxygen and 5% CO 2 . The cells were then transfected with 10 μg of plasmid vector pcDNApUbiFKBP12cTKpCMVnTK V119C FRB using Lipofectamine 2000 transfection reagent (Invitrogen), and 24 h later the medium was replaced with fresh medium containing 10 μg ml −1 puromycin (SigmaAldrich). Every 2 d, the medium was changed and replaced with fresh medium containing puro mycin. The steps were repeated until we achieved 100% puromycin resistant cells. The cells were checked for the expression of split thymidine kinase with the interacting proteins using the [8 3 H]penciclovir cell uptake assay before and after exposure of cells to 40 nM rapamycin.
Western immunoblotting. Stably transfected cell samples were also lysed, and expression levels of FRB (mTOR) and FKBP12 (either endogenous or in their fusion with split thymidine kinase fragments) in total lysates were determined by immunoblotting with antibody to thymidine kinase (1 in 500, polyclonal, raised in rabbit) for nTKFRB and FKBP12cTK, antibody to FRB (Cell Signaling) for cellular FRB (mTOR), antibody to FKBP12 (Abcam) for cellular FKBP12 and antibody to αtubulin or βactin (Sigma) as an internal control for loading.
Nuclear and cytoplasmic extraction.
A Thermo Scientific NEPER kit was used for nuclear and cytoplasmic extraction of proteins. Extracts obtained with this product have less than 10% contamination between nuclear and cytoplasmic fractions. These extracts were further analyzed by western blotting for protein expression. Figure 2a . Fortyeight hours later, the cells were fixed with acetone for 2 min, after which this was made to evaporate by keeping at 20 °C. for 10 min. The cells were blocked by incubating with Trisbuffered saline with Tween (TBST) containing 2% BSA for 60 min at 20 °C. The cells were further incubated in TBST with 2% BSA containing antibody to thymidine kinase (1 in 500, poly clonal, raised in rabbit) for an additional 60 min. They were washed three times (5 min each) with TBST. The cells were then incubated with TBST containing fluoresceinlabeled secondary goat antibody to rabbit (1 in 200; Chemicon) for 60 min at 20 °C. Fluorescent microscopy (using an excitation filter at 365 nm) of washed cells was performed with an Axiovert 25 microscope (Carl Zeiss AG), and micrographs were obtained at × 40 magnification with an AxioCam MRc camera (Bernried).
Immunostaining and fluorescence microscopy of cells for subcellular localization of components of the thymidine kinase protein-fragment complementation assay. 293T cells were transfected with the vectors depicted in
MicroPET imaging in living mice. All mouse handling and care was per formed in accordance with Stanford University Animal Research Committee guidelines. For imaging studies using stable cell lines, five 12week old female nude mice (nu/nu) were implanted subcutaneously over the left shoulder with 5 × 10 6 mocktransfected 293T cells admixed with 50,000 293T stable cells expressing firefly luciferase (see below) and subcutaneously over the right shoulder with 5 × 10 6 293T stable cells expressing both nTK V119C FRB and FKBP12cTK admixed with 50,000 293T stable cells expressing firefly luciferase. The cells were allowed to grow as tumors for 7 d (to ~0.3-0.4 cm in diameter). On day 8, mice were tailvein-injected with 200 μCi of [ 18 F] FHBG after undergoing anesthesia with 2% isoflurane in oxygen at 2 l min −1 . Three hours later, mice were microPETimaged in a spread prone position in a FOCUS microPET scanner (Concorde Microsystems). Images were reconstructed using a threedimensional filtered back projection and itera tive maximum a posteriori algorithm and no partial volume correction 27 . Immediately after imaging, the mice were intraperitoneally injected with 50 μg of rapamycin; 24 h later, all of the mice were resubjected to microPET imaging as mentioned above. The mice were further injected with intraperitoneal 50 μg rapamycin for 2 d more at 24h intervals and subjected to repeat microPET imaging. In a separate cohort of four control mice, the above temporal imaging studies were performed in an identical fashion, except that no rapamycin was administered. The counts from regions of interest were converted to the percentage injected dose per g of tumor using filtered back projection as described previously 27 . The percentage injected dose per g is a measure of the amount of tracer accumulated in a given tissue site normalized to the injected amount and to the mass of the tissue examined. The FHBG accumulation in the 293T tumor cells reflects their thymidine kinase activity. For statistical analysis we used the twotailed Student's t test. Differences were considered significant at P < 0.05.
For imaging in these five mice, 293T cells stably expressing firefly luci ferase enzyme were used as secondary gene-marked cells to report on overall tumor viability when admixed with 293T cells stably expressing split thymidine kinase plus the interacting proteins FRB and FKBP12. We therefore used firefly luciferase activity measured by optical CCD camera imaging as an indirect crude measure of the viability and adequacy of cell number of admixed 293T cells acting as the source of the microPET images. Mice were imaged in the prone position after tailvein injection of 4 mg dluciferin per mouse. Each mouse was implanted subcutaneously over the left shoulder with 5 × 10 6 mock transfected 293T cells admixed with 50,000 293T stable cells expressing firefly luciferase and subcutaneously over the right shoulder with 5 × 10 6 293T stable cells expressing both nTK V119C FRB and FKBP12cTK admixed with 50,000 293T stable cells expressing firefly luciferase. Details of optical imaging are as reported previously 9 . We removed the tumors from the mice after microPET imaging for immunostaining to confirm the expression of split thymidine kinase protein within the tumors.
Statistical analyses. We used the twotailed Student's t test for all statistical analyses. Differences were considered significant at P < 0.05.
Additional methods. Detailed methodology is described in the Supplementary Methods and elsewhere 15 . 
